Provided by Tiger Fintech (Singapore) Pte. Ltd.

Design Therapeutics, Inc.

3.40
-0.1200-3.41%
Post-market: 3.400.00000.00%16:02 EDT
Volume:114.42K
Turnover:390.13K
Market Cap:192.99M
PE:-3.88
High:3.66
Open:3.41
Low:3.30
Close:3.52
Loading ...

Top Premarket Gainers

MT Newswires Live
·
02 Apr

RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
11 Mar

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

Benzinga
·
10 Mar

BRIEF-Design Therapeutics Q4 Basic EPS USD -0.24

Reuters
·
10 Mar

Design Therapeutics Q4 Net Income USD -13.651 Million

THOMSON REUTERS
·
10 Mar

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
10 Mar

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

GlobeNewswire
·
03 Mar

3 Promising US Penny Stocks With Market Caps Under $900M

Simply Wall St.
·
22 Jan

Top Premarket Decliners

MT Newswires Live
·
30 Dec 2024

Investors Look to Reverse Last Week's Slide as US Futures Mixed Monday Pre-Bell

MT Newswires Live
·
23 Dec 2024

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

GlobeNewswire
·
13 Nov 2024

Cautious Optimism for Design Therapeutics Amid Promising Developments and Financial Challenges

TIPRANKS
·
11 Nov 2024

Design Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Design Therapeutics Reports Strong Q3 and Pipeline Progress

TIPRANKS
·
08 Nov 2024

BRIEF-Design Therapeutics Q3 Basic EPS USD -0.23

Reuters
·
08 Nov 2024

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-Term Milestones for Genetactm Portfolio

THOMSON REUTERS
·
08 Nov 2024

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

GlobeNewswire
·
08 Nov 2024